Key result
Switching to dabigatran linked to ~2 percentage points fewer inpatient visits than switching to rivaroxaban.
Why the study?
Switching from warfarin to NOACs is common in non-valvular atrial fibrillation, but differences in the effect of individual NOACs on all-cause healthcare resource utilization remain unknown.
Does switching to dabigatran compared to rivaroxaban or apixaban reduce healthcare resource utilization in patients with non-valvular atrial fibrillation previously on warfarin?
Cohort (n=28,880)
Does switching to dabigatran compared to rivaroxaban or apixaban reduce healthcare resource utilization in patients with non-valvular atrial fibrillation previously on warfarin?
In a real-world US claims analysis, switching from warfarin to dabigatran was associated with slightly lower outpatient and emergency department healthcare resource utilization compared to switching to rivaroxaban or apixaban.
Answers are grounded in this paper and cite their sources.
May reduce inpatient visits after warfarin-to-dabigatran switch versus rivaroxaban in nonvalvular AF; leaves open confirmation in randomized trials or versus apixaban.
Among patients with non-valvular atrial fibrillation (NVAF), switching from warfarin to novel oral anticoagulants (NOACs) is common, yet clarifying the differences in the effect of NOACs on all-cause healthcare resource utilization (HCRU) are unknown. Adult NVAF patients who switched from warfarin to dabigatran, apixaban, or rivaroxaban were identified in MarketScan databases between 10/2010-12/2015. Patients had 12 months pre-period (index date was 1st NOAC claim) and were followed up to 12 months until medication discontinuation, end of enrollment, inpatient death, or 12/2016. Overall, 8,679 and 5,761 dabigatran switchers were matched (1:1) to rivaroxaban and apixaban switchers (mean age 73-74 years). Compared with rivaroxaban switchers, a lower proportion of dabigatran switchers had an inpatient (IP) visit (20.0% vs. 21.6%, p=0.008). Dabigatran switchers had lower per-patient-per-month (PPPM) total outpatient (3.87 vs. 4.06, p=0.002), emergency department (ED; 0.48 vs. 0.52, p=0.026), outpatient office (1.17 vs. 1.22, p<0.001), and other outpatient (2.71 vs. 2.83, p=0.043) visits compared with rivaroxaban switchers. A similar proportion of dabigatran and apixaban switchers had an IP visit (20.7% vs. 21.2%); compared with apixaban switchers, dabigatran switchers had significantly more PPPM IP visits (0.23 vs. 0.21, p=0.031) but significantly lower ED visits (0.47 vs. 0.52, p=0.016). Post-discharge 30-day readmission rates were comparable among warfarin-to-NOAC switching groups. Time to readmission was longer for dabigatran versus rivaroxaban switchers (8.2 vs. 7.8 days, p<0.001), but comparable with apixaban patients (8.1 vs. 8.4 days). Switching to dabigatran after warfarin discontinuation may lower HCRU among NVAF patients compared with switching to rivaroxaban or apixaban.
No takes yet. Share an insight, caveat, or question.
Franchino‐Elder et al. (2019) conducted a cohort in Non-valvular atrial fibrillation (n=28,880). Dabigatran vs. Rivaroxaban was evaluated on Proportion of patients with an inpatient visit (p=0.008). Switching from warfarin to dabigatran in patients with non-valvular atrial fibrillation was associated with a lower proportion of inpatient visits compared to switching to rivaroxaban.
Synapse has enriched 10 related papers. Consider them for comparative context: